In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response
Fig 10
Tumor-specific CTLs in blood of B16 melanoma-bearing mice after CpG/ CpG-construct treatment.
Injection of 1x10^6 B16 melanoma cells s.c. followed by repetitive daily treatment with 1 nmol CpG/ CpG-scrambled RNA/ CpG-siRNA A20 for 7 days started on day 4; blood collected for cellular analyses on day 10. Tumor-specific CD8+ T cells detected by Trp-1 multimer staining. (A) Mean percentage of total and Trp-1 specific CTLs (6 mice/group); n.s. indicates not significant, *indicates p<0.05 compared to CpG. Shown are results from one representative experiment. (B) Dot plots showing percentage of CTLs and Trp-1 specific CTLs in peripheral blood lymphocytes (one representative animal per group).